Biotech | March 21, 2022
Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK
The facility will produce 150 million vaccine doses per year
The facility will produce 150 million vaccine doses per year
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
Subscribe To Our Newsletter & Stay Updated
